Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE (ARGX) is a global immunology leader developing antibody-based therapies for rare autoimmune diseases and neuromuscular disorders. This page provides real-time news updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the company’s trajectory.
Investors and industry professionals will find a curated collection of press releases, earnings reports, and partnership announcements. Key focus areas include updates on treatments for myasthenia gravis, CIDP, and thyroid eye disease, alongside innovations like subcutaneous formulations enhancing patient care.
Our repository ensures access to verified developments in ARGX’s clinical pipeline, FDA/EMA interactions, and research collaborations. Content is organized for quick scanning while maintaining scientific accuracy, balancing technical detail with investor-centric insights.
Bookmark this page for streamlined tracking of ARGX’s progress in advancing immunology solutions. Check regularly for authoritative updates on trial results, commercialization efforts, and industry recognition driving the company’s global impact.
argenx (NASDAQ:ARGX) reported strong Q2 2025 financial results, with global product net sales reaching $949 million, representing 97% year-over-year growth. The company achieved $245 million in quarterly profit, with earnings per share of $4.02.
VYVGART SC launch in CIDP has gained momentum with over 2,500 patients on treatment globally. The company announced positive proof-of-concept data for ARGX-119 in CMS, advancing to a registrational study. argenx maintains its Vision 2030 goal of treating 50,000 patients globally, securing 10 labeled indications, and advancing five pipeline candidates to Phase 3.
The company's R&D and SG&A guidance remains at $2.5 billion, with six registrational and six proof-of-concept readouts expected by end of 2026.
argenx (Euronext & Nasdaq: ARGX), a global immunology company, will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and second quarter business update.
The webcast will be accessible through the Investors section of the argenx website at argenx.com/investors, with a replay available for approximately one year. The company has provided international dial-in numbers and the access code 3810049 for participants, who are advised to dial in 15 minutes before the call.
argenx SE (Nasdaq: ARGX) announced plans to advance ARGX-119, their first-in-class agonist antibody targeting muscle-specific kinase (MuSK), to a registrational study for congenital myasthenic syndromes (CMS) following positive Phase 1b results.
The Phase 1b multicenter, randomized, double-blinded, placebo-controlled trial demonstrated a favorable safety and tolerability profile for ARGX-119. The study showed consistent improvements in DOK7-CMS patients across multiple efficacy measures throughout the 12-week study period, including Six-Minute Walk Test, Quantitative Myasthenia Gravis score, and Myasthenia Gravis Activities of Daily Living score.
The trial design included a 4:1 randomization to ARGX-119 or placebo, with an 11-month duration comprising screening, treatment, and follow-up periods. ARGX-119 represents the sixth successful molecule developed through argenx's Immunology Innovation Program (IIP), validating their collaborative discovery model.
argenx SE (Euronext & Nasdaq: ARGX) held its Annual General Meeting of shareholders on May 27, 2025, with 91.1% of the company's share capital represented. Most agenda items received majority approval, except for the remuneration policy (agenda item 5) which received 73.0% approval, falling short of the required 75% threshold.
Key approved resolutions included: the 2024 remuneration report (76.7% in favor), 2024 annual report and accounts (99.9% approval), re-appointment of Anthony Rosenberg as non-executive director (93.6% approval), and authorization for the Board to issue shares up to 10% of outstanding share capital (99.4% approval).
argenx (ARGX), a global immunology company focused on severe autoimmune diseases, has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Tim Van Hauwermeiren and other management team members will deliver a presentation on Tuesday, May 13, 2025, at 4:20 p.m. PT.
The presentation will be accessible through a live webcast on the Investors section of argenx's website at argenx.com/investors. A replay will remain available for approximately 30 days after the event.
[]argenx, a global immunology company focused on developing treatments for severe autoimmune diseases, has scheduled its first quarter 2025 financial results and business update conference call for May 8, 2025.
The conference call and audio webcast will take place at 2:30 p.m. CET (8:30 a.m. ET). Investors and interested parties can access the live webcast through the Investors section of the argenx website. A replay will remain available on the website for approximately one year.
For direct participation, the company has provided international dial-in numbers for multiple countries including:
- United States: 1 888 415 4250
- United Kingdom: 44 800 358 0970
- Belgium: 32 800 50 201
- Japan: 81 3 4578 9081